@mariposa2-rossa.bsky.social

Ho una @mariposa2-rossa.bsky.social in bolla ma non trovo riferimenti... Spe', leggo 'piu meglio'

A comprehensive review of evidence supporting EGFR inhibitors in NSCLC
✅ Neoadjuvant - EMERGING
✅ Adjuvant - ADAURA
✅ Unresectable - LAURA
✅ Metastatic - FLAURA, PAPILLON, ACHILLES
✅ Resistant(on vs off target) - MARIPOSA2, HARMONI, immunorx

#lung #cancer #lcsm #oncsky

Updated #ASCO living guideline for Stage4 #NSCLC ŵ driver mutation

Incorporates findings of #MARIPOSA & #MARIPOSA2: recommends considering Amivantamab in 1° and 2° #EGFR settings with Ex19 or L858R. Both studies improved PFS, OS immature

#medsky #oncsky #lungcancer

ascopubs.org/doi/pdf/10.1...

Grazie @mariposa2-rossa.bsky.social

Trials in EGFR Mutated NSCLC: Mariposa2 and Laura- 2024 Leading Developments in Lung Cancer youtu.be/x_SWNsgkfag?... via @YouTube

In this video, Drs. Desai and Abu Rous discuss trial dates from Mariposa2 and Laura as presented at 2024 ASCO, and the implications in treating EGFR+ NSCLC.

Nice report, but these are subject to selection bias, access amplifies socioeconomic disparities, and retrospective analyses show association, but not causation. I do think it is reasonable and have done it routinely - though now, MARIPOSA2 with amivantamab + chemotherapy (below) is my standard.

Best of Oncology East Conference content now live! Explore the latest #LungCancer updates presented by Dr. Jeff Rothenstein, feat. insights on key studies, including:

ADRIATIC
DELPHI-301
LAURA
POLESTAR
MARIPOSA2
PALOMA-3
CROWN
HARMONi

Full session: ow.ly/vpB650UnKyp

#BoOE24 #MedOnc #OncEd